Research and Clinical Trials

The following are Industry Sponsored Clinical Research (ISR) currently conducted at the various centres. For further information, please contact the Principal Investigator.

TYPE TITLE SHORT TITLE SITE PRINCIPAL INVESTIGATOR CONTACT LINKS
Muscle-invasive bladder cancer A phase 3, randomized, double-blind, placebo-controlled clinical trial to study the efficacy and safety of pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT alone in participants with muscle-invasive bladder cancer (MIBC) (KEYNOTE-992) KEYNOTE-992 Kuala Lumpur Hospital (HKL) DR MUTHUKKUMARAN A/L THIAGARAJAN +603 – 2615 5555, Ext. 1782
/ 1783
/ +60 17-233 6295 (Amirah)
CLICK HERE
Muscle-invasive bladder cancer A phase 3, randomized, double-blind, placebo-controlled clinical trial to study the efficacy and safety of pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT alone in participants with muscle-invasive bladder cancer (MIBC) (KEYNOTE-992) KEYNOTE-992 Pulau Pinang Hospital DR
SOO HOO HWOEI FEN
+604 – 2225 767
/ 2225 762
/ 2225 766
/ 2225 586
CLICK HERE
TYPE TITLE SHORT TITLE SITE PRINCIPAL INVESTIGATOR CONTACT LINKS
Metastatic breast cancer A phase II randomized study of the combination of Ribociclib plus goserelin acetate with Hormonal Therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with hormone receptor-positive/HER2-negative inoperable locally advanced or metastatic breast cancer RIGHT CHOICE Kuala Lumpur Hospital (HKL) DR MALWINDER SINGH SANDHU +603 – 2615 5555, Ext. 1782
/ 1783
CLICK HERE
Metastatic breast cancer A phase II randomized study of the combination of Ribociclib plus goserelin acetate with Hormonal Therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with hormone receptor-positive/HER2-negative inoperable locally advanced or metastatic breast cancer RIGHT CHOICE Sarawak General Hospital DR VOON PEI JYE +608 – 2276 820 CLICK HERE
Metastatic breast cancer A phase II randomized study of the combination of Ribociclib plus goserelin acetate with Hormonal Therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with hormone receptor-positive/HER2-negative inoperable locally advanced or metastatic breast cancer RIGHT CHOICE Sultan Ismail Hospital, Johor Bahru DR LIM CHUN SEN +607 – 3565 155 CLICK HERE
Metastatic breast cancer A phase II randomized study of the combination of Ribociclib plus goserelin acetate with Hormonal Therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with hormone receptor-positive/HER2-negative inoperable locally advanced or metastatic breast cancer RIGHT CHOICE Hospital Wanita dan Kanak-Kanak Sabah DR FLORA CHONG LI TZE +608 – 8522 600, Ext. 2272 CLICK HERE
TYPE TITLE SHORT TITLE SITE PRINCIPAL INVESTIGATOR CONTACT LINKS
Metastatic adenocarcinoma and squamous cell carcinoma of the esophagus A phase III randomized open-label study of single agent pembrolizumab vs physicians’ choice of single agent docetaxel, paclitaxel, or irinotecan in subjects with advanced/metastatic adenocarcinoma and squamous cell carcinoma of the esophagus that have progressed after first-line standard therapy (KEYNOTE-181) MK3475-181 Sultan Ismail Hospital, Johor Bahru DR LIM CHUN SEN +607 – 3565 155 CLICK HERE
TYPE TITLE SHORT TITLE SITE PRINCIPAL INVESTIGATOR CONTACT LINKS
Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma GLOW Kuala Lumpur Hospital (HKL) DR NOOR ZAFIFAH BINTI ZAKARIA +603 – 2615 5555, Ext. 1620
/ 1144
CLICK HERE
Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma GLOW Pantai Hospital Kuala Lumpur DR MASTURA BINTI MD YUSOF +603 – 2296 0764
/ 0800
CLICK HERE
Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma GLOW Pulau Pinang Hospital DR SOO HOO HWOEI FEN  +604 – 2225 767
/ 2225 762
/ 2225 766
/ 2225 586
CLICK HERE
Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma GLOW Hospital Wanita dan Kanak-Kanak Sabah DR SUCHARIT PONGPRAKYUN +608 – 8522 600, Ext. 2272 CLICK HERE
TYPE TITLE SHORT TITLE SITE PRINCIPAL INVESTIGATOR CONTACT LINKS
Head and Neck Squamous Cell Carcinoma The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN) KO-TIP-007 National Cancer Institute (IKN) DR SUHANA BINTI YUSAK +603 – 88925555, Ext. 4168 CLICK HERE
TYPE TITLE SHORT TITLE SITE PRINCIPAL INVESTIGATOR CONTACT LINKS
Hepatocellular Carcinoma A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937) KEYNOTE-937 National Cancer Institute (IKN) DR WONG YOKE FUI, Florence +603 – 8892 5555, Ext. 4168 CLICK HERE
Hepatocellular Carcinoma A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937) KEYNOTE-937 Sarawak General Hospital DR LIM YUEH NI +608 – 2276 820 CLICK HERE
Unresectable biliary tract carcinoma A phase 3 randomized, double blind study of pembrolizumab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin as first-line therapy in participants with advanced and/or unresectable biliary tract carcinoma KEYNOTE-966 Kuala Lumpur Hospital (HKL) DR VAISHNAVI A/P JEYASINGAM +603 – 2615 5555, Ext 1620
/ 1144
CLICK HERE
Unresectable biliary tract carcinoma A phase 3 randomized, double blind study of pembrolizumab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin as first-line therapy in participants with advanced and/or unresectable biliary tract carcinoma KEYNOTE-966 National Cancer Institute (IKN) DR TAN CHIH KIANG +603 – 8892 5418
/ +603 – 8892 5555, Ext. 4168
CLICK HERE
Unresectable biliary tract carcinoma A phase 3 randomized, double blind study of pembrolizumab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin as first-line therapy in participants with advanced and/or unresectable biliary tract carcinoma KEYNOTE-966 Pantai Hospital Kuala Lumpur DR JOHN LOW SENG HOOI +603 – 2296 0800 CLICK HERE
Unresectable biliary tract carcinoma A phase 3 randomized, double blind study of pembrolizumab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin as first-line therapy in participants with advanced and/or unresectable biliary tract carcinoma KEYNOTE-966 Pulau Pinang Hospital DR TAN AI LIAN  +604 – 2225 767
/ 2225 762
/ 2225 766
/ 2225 586
CLICK HERE
Non-small cell lung cancer A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC) CANOPY A Pantai Hospital Kuala Lumpur DR MASTURA BINTI MD YUSOF +603 – 2296 0764
/ 0800
CLICK HERE
TYPE TITLE SHORT TITLE SITE PRINCIPAL INVESTIGATOR CONTACT LINKS
Non-small cell lung cancer A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC) CANOPY A Pulau Pinang Hospital DR TAN AI LIAN  +604 – 2225 767
/ 2225 762
/ 2225 766
/ 2225 586
CLICK HERE
Non-small cell lung cancer A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC) CANOPY A Sarawak General Hospital DR SYADWA BINTI ABDUL SHUKOR +608 – 2276 820 CLICK HERE
Metastatic non-small cell lung cancer A randomized, open label, multicenter phase II study evaluating the efficacy and safety of capmatinib (INC280) plus pembrolizumab versus pembrolizumab alone as first line  treatment for locally advanced or metastatic non-small cell lung cancer with PD-L1 >= 50% CINC280I12201 Sarawak General Hospital DR SYADWA BINTI ABDUL SHUKOR +608 – 2276 820 CLICK HERE
Non-Small Cell Lung Cancer A phase II single-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior 1st to 3rd generation EGFR-tyrosine kinase inhibitor therapy MS200095-0031 Pantai Hospital Kuala Lumpur DR THO LYE MUN +603 – 2296 0800 CLICK HERE
Non-Small Cell Lung Cancer A phase II single-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior 1st to 3rd generation EGFR-tyrosine kinase inhibitor therapy MS200095-0031 Sarawak General Hospital DR SYADWA BINTI ABDUL SHUKOR +608 – 2276 820 CLICK HERE
Non-Small Cell Lung Cancer A phase II single-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior 1st to 3rd generation EGFR-tyrosine kinase inhibitor therapy MS200095-0031 Tengku Ampuan Afzan Hospital, Kuantan PROF DR HOW SOON HIN +609 – 5572 922 CLICK HERE
Non-Small Cell Lung Cancer A phase II single-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior 1st to 3rd generation EGFR-tyrosine kinase inhibitor therapy MS200095-0031 Pulau Pinang Hospital DR IRFHAN ALI B HYDER ALI  +604 – 2225 767
/ 2225 762
/ 2225 766
CLICK HERE
Non-squamous Non-small Cell Lung Cancer A Randomized, Double-blind, Parallel Group, Equivalence, Multicenter Phase III Trial to Compare the Efficacy, Safety,Pharmacokinetics and Immunogenicity of HD204 to Avastin® in patients with Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer SAMSON-II Raja Perempuan Zainab II Hospital, Kota Bharu DR AZZA BINTI OMAR  +609 – 7452 636  
Non-squamous Non-small Cell Lung Cancer A Randomized, Double-blind, Parallel Group, Equivalence, Multicenter Phase III Trial to Compare the Efficacy, Safety,Pharmacokinetics and Immunogenicity of HD204 to Avastin® in patients with Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer SAMSON-II Pulau Pinang Hospital DR IRFHAN ALI B HYDER ALI  +604 – 2225 767
/ 2225 762
/ 2225 766
 
Non-squamous Non-small Cell Lung Cancer A Randomized, Double-blind, Parallel Group, Equivalence, Multicenter Phase III Trial to Compare the Efficacy, Safety,Pharmacokinetics and Immunogenicity of HD204 to Avastin® in patients with Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer SAMSON-II Kuala Lumpur Hospital (HKL) DR PRATHEPAMALAR A/P YEHGAMBARAM +603 – 2615 5555, Ext. 1620
/ 1144
 
Metastatic Non-Small Cell Lung Cancer A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer 61186372NSC3001 (Papillon) Sultan Ismail Hospital, Johor Bahru DR LIM CHUN SEN  +607 – 3565 155 CLICK HERE
Metastatic Non-Small Cell Lung Cancer A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer 61186372NSC3001 (Papillon) Kuala Lumpur Hospital (HKL) DR MUTHUKKUMARAN A/L THIAGARAJAN +603 – 2615 5555, Ext. 1782
/ 1783
/ +60 17-233 6295 (Amirah)
CLICK HERE
Metastatic Non-Small Cell Lung Cancer A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer 61186372NSC3001 (Papillon) Pulau Pinang Hospital DR SOO HOO HWOEI FEN  +604 – 2225 767
/ 2225 762
/ 2225 766
/ 2225 586
CLICK HERE
Metastatic Non-Small Cell Lung Cancer A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Single Agent Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (MARIPOSA) 73841937NSC3003 (Mariposa) Sultan Ismail Hospital, Johor Bahru DR LIM CHUN SEN  +607 – 3565 155 CLICK HERE
Metastatic Non-Small Cell Lung Cancer A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Single Agent Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (MARIPOSA) 73841937NSC3003 (Mariposa) Kuala Lumpur Hospital (HKL) DR MUTHUKKUMARAN A/L THIAGARAJAN +603 – 2615 5555, Ext 1782
/ 1783
/ +60 17-233 6295 (Amirah)
CLICK HERE
Metastatic Non-Small Cell Lung Cancer A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Single Agent Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (MARIPOSA) 73841937NSC3003 (Mariposa) Tengku Ampuan Afzan Hospital, Kuantan PROF DR HOW SOON HIN +609 – 5572 922 CLICK HERE
Metastatic Non-Small Cell Lung Cancer A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Single Agent Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (MARIPOSA) 73841937NSC3003 (Mariposa) Pulau Pinang Hospital DR SOO HOO HWOEI FEN  +604 – 2225 767
/ 2225 762
/ 2225 766
/ 2225 586
CLICK HERE
Metastatic non-small cell lung cancer A Single-Arm, Open-Label, Phase 2 Study of Dacomitinib with or without dose titration for the first-line treatment of locally advanced or metastatic non-small cell lung cancer in subjects with an epidermal growth factor receptor (EGFR) activation mutation ATORG-003 Sarawak General Hospital DR LIM YUEH NI +608 – 2276 820 CLICK HERE
Non-Small Cell Lung Cancer (Stage III) Phase III, randomized, double-blind, placebo-controlled, multicenter, international study of osimertinib as maintenance therapy in patients with locally advanced, unresectable EGFR mutation-positive Non-Small Cell Lung Cancer (Stage III) whose disease has not progressed following definitive platinum-based chemoradiation therapy (LAURA) LAURA Kuala Lumpur Hospital (HKL) DR IBTISAM MUHAMAD NOR +603 – 2615 5555, Ext. 1620
/ 1144
CLICK HERE
Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer (POD1UM-304) INCMGA0012-304 Tengku Ampuan Afzan Hospital, Kuantan DR AISHAH BINTI IBRAHIM +609 – 5572 922 CLICK HERE
Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer (POD1UM-304) INCMGA0012-304 Sarawak General Hospital DR HENG FOOK YEW +608 – 2276 820 CLICK HERE
Non-small Cell Lung Cancer A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/- Pembrolizumab (MK-3475) as Neoadjuvant/ Adjuvant Therapy for Participants with Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671) MK-3475-671 Sarawak General Hospital DR HENG FOOK YEW +608 – 2276 820 CLICK HERE
TYPE TITLE SHORT TITLE SITE PRINCIPAL INVESTIGATOR CONTACT LINKS
Ovarian Cancer Clinical Validation of the Venn Ovarian Cancer Liquid Biopsy:  VOCAL Study OVACA-001 Hospital Wanita dan Kanak-Kanak Sabah DR SOON RUEY +608 – 8522 600, Ext. 2272 CLICK HERE
Ovarian Cancer Clinical Validation of the Venn Ovarian Cancer Liquid Biopsy:  VOCAL Study OVACA-001 Miri Hospital DR HARRIS ROLAND DEMONG +608 – 5413 673, Ext. 520 CLICK HERE
Ovarian Cancer Clinical Validation of the Venn Ovarian Cancer Liquid Biopsy:  VOCAL Study OVACA-001 Selayang  Hospital DR NOR ELYANA NOORDIN +603 – 6126 3333, Ext. 4318
/ 4314
/ 4181
CLICK HERE
Ovarian Cancer Clinical Validation of the Venn Ovarian Cancer Liquid Biopsy:  VOCAL Study OVACA-001 Seberang Jaya Hospital DR SALINA BINTI SANY +604 – 3827 333, Ext: 511 CLICK HERE
Ovarian Cancer Clinical Validation of the Venn Ovarian Cancer Liquid Biopsy:  VOCAL Study OVACA-001 Sibu Hospital DR SII LEH PING + 608 – 4343 333 CLICK HERE
Ovarian Cancer Clinical Validation of the Venn Ovarian Cancer Liquid Biopsy:  VOCAL Study OVACA-001 Sultan Ismail Hospital, Johor Bahru DR NOR HIDAYAH BT YAYANTO +607 – 3565 155 CLICK HERE
Ovarian Cancer Clinical Validation of the Venn Ovarian Cancer Liquid Biopsy:  VOCAL Study OVACA-001 Raja Perempuan Zainab II Hospital, Kota Bharu DR NIK AHMAD BIN NIK ABDULLAH +609 – 7452 636 CLICK HERE
Ovarian Cancer Clinical Validation of the Venn Ovarian Cancer Liquid Biopsy:  VOCAL Study OVACA-001 Sarawak General Hospital DR SIM WEE WEE +608 – 2276 820 CLICK HERE
Ovarian Cancer Clinical Validation of the Venn Ovarian Cancer Liquid Biopsy:  VOCAL Study OVACA-001 Taiping Hospital DR NORLIA BINTI MOHAMAD +605 – 8204 029 CLICK HERE
Ovarian Cancer Clinical Validation of the Venn Ovarian Cancer Liquid Biopsy:  VOCAL Study OVACA-001 Raja Permaisuri Bainun Hospital, Ipoh DR LEE SAW JOO +605 – 2085 146 CLICK HERE
Ovarian Cancer Clinical Validation of the Venn Ovarian Cancer Liquid Biopsy:  VOCAL Study OVACA-001 Ampang Hospital DR YONG CHEE MENG +603 – 4289 6559
/ 6560
CLICK HERE
Ovarian Cancer Clinical Validation of the Venn Ovarian Cancer Liquid Biopsy:  VOCAL Study OVACA-001 Tengku Ampuan Afzan Hospital, Kuantan DR YONG SOON LEONG +609 – 5572 922 CLICK HERE
TYPE TITLE SHORT TITLE SITE PRINCIPAL INVESTIGATOR CONTACT LINKS
Metastic Prostate Cancer A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer MAGNITUDE Kuala Lumpur Hospital (HKL) DR VIJAYAN MANOGRAN @ MANOHARAN +603 – 2615 5555, Ext. 1620
/ 1144
CLICK HERE
Metastic Prostate Cancer A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer MAGNITUDE Pulau Pinang Hospital DR SOO HOO HWOEI FEN  +604 – 2225 767
/ 2225 762
/ 2225 766
/ 2225 586
CLICK HERE
Metastic Prostate Cancer A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer MAGNITUDE Sultan Ismail Hospital, Johor Bahru DR LIM CHUN SEN  +607 – 3565 155 CLICK HERE
Metastic Prostate Cancer A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer MAGNITUDE Hospital Wanita dan Kanak-Kanak Sabah DR FLORA CHONG LI TZE +608 – 8522 600 Ext. 2272 CLICK HERE
Metastatic Prostate Cancer Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer 64091742PCR0002 Sarawak General Hospital DR HADI BIN AB.JALIL +604 – 2225 767
/ 2225 762
/ 2225 766
/ 2225 586
/ 276 820
CLICK HERE
Metastatic Prostate Cancer Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer 64091742PCR0002 Pulau Pinang Hospital DR SOO HOO HWOEI FEN  +604 – 2225 767
/ 2225 762
/ 2225 766
/ 2225 586
CLICK HERE
Metastatic Prostate Cancer Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer 64091742PCR0002 Kuala Lumpur Hospital (HKL) DR MUTHUKKUMARAN A/L THIAGARAJAN +603 – 2615 5555, Ext. 1782
/ 1783
/ +60 17-233 6295 (Amirah)
CLICK HERE
Metastatic Castration-Sensitive Prostate Cancer Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) AMPLITUDE Sarawak General Hospital DR HADI BIN AB.JALIL +608 – 227 6666
/ 6035
/ 276 820
CLICK HERE
Metastatic Castration-Sensitive Prostate Cancer Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) AMPLITUDE National Cancer Institute (IKN) DR ARNIL GEORGE SIRIMANNE +603 – 8892 5555, Ext. 4168 CLICK HERE
Metastatic Castration-Sensitive Prostate Cancer Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) AMPLITUDE Pulau Pinang Hospital DR FONG CHIN HENG  +604 – 2225 767
/ 2225 762
/ 2225 766
CLICK HERE
Metastatic Castration-Sensitive Prostate Cancer Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) AMPLITUDE Kuala Lumpur Hospital (HKL) DR PRATHEPAMALAR A/P YEHGAMBARAM +603 – 2615 5555, Ext. 1620
/ 1144
CLICK HERE

The information above was last updated on 20 May 2021.

Source: http://clinicalresearch.my/

Links are from CLINICALTRIAL.GOV